OMB No. 0925-0001 and 0925-0002 (Rev. 11/16 Approved Through 10/31/2018)

BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Vincent Philip Gullo eRA COMMONS USER NAME (credential, e.g., agency login): vgullo POSITION TITLE: Research Fellow, Research Institute for Scientists Emeriti, Drew University

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) DEGREE Completion (if Date FIELD OF STUDY INSTITUTION AND LOCATION applicable) MM/YYYY

City College of New York BS 06/1971 Chemistry

Columbia University MA 06/1972 Chemistry

Columbia University PhD 06/1975 Chemistry

A. Personal Statement

My professional activity in pharmaceutical and academic research has focused on drug discovery that includes a passion to communicate the excitement of drug discovery to my colleagues and future researchers. After receiving my PhD in Organic Chemistry from Columbia University, I joined the Merck Research Laboratories. With a strong background in natural products chemistry, I worked on the isolation and structural elucidation of compounds from microbial sources found active in a variety of therapeutic areas, including anti-infectives, anti- inflammatories, anti-parasitic agents and cholesterol lowering drugs. Fortunately, I was a member of the team that discovered 3 marketed products: primaxin, a broad spectrum antibiotic, mevacor, the first cholesterol lowering agent (statin) and the anthelmintic, ivermectin. For the latter discovery, Dr. William Campbell, our leader in this project, was awarded the 2015 Nobel Prize in Medicine for the treatment worldwide of the devastating disease, river blindness. In 1983, I had the opportunity to lead the natural products group at Schering Plough Research Institute (SPRI) as an Assistant Director. The natural products group at Schering Plough developed new therapeutic assays, isolated and fermented microorganisms, screened extracts for bioactivity and through bioassay guided fractionation, isolated and identified bioactive compounds. With the advent of high throughput screening and combinatorial chemistry, the natural product group was ideally suited to expand their role and became the department of New Lead Discovery at SPRI. In this capacity, many compounds were identified and progressed from drug discovery to the clinic. In 2003 I joined Cetek Corporation to become Vice President of Drug Discovery. My role was to lead the research teams in all phases of drug discovery, from therapeutic target selection to compound recommendations for the clinic. At Cetek the research team discovered two novel compounds for development, an anticancer compound and an antiviral compound. The anticancer compound was licensed to a large pharmaceutical company for further development. I’ve always enjoyed sharing my excitement for drug discovery. In addition to coauthoring over 100 research publications, presentations and patents, I’ve served in leadership roles in American Society for Microbiology and the Society for Industrial Microbiology and Biotechnology (SIMB). Especially meaningful for me, was my five year role as Special Conference Chair for SIMB where we established new meetings in the fields of natural

products and fermentation technology. In 2011, I received the Charles Porter Award from the SIMB for my service to this organization. In 2007 I joined Drew University as a Research Fellow in the Research Institute for Scientists Emeriti (RISE). At Drew I enjoy mentoring students in the laboratory in the area of antibacterial drug discovery. Projects include the synthesis of novel antibacterial compounds and antibacterial discovery from microbial sources. I am also currently a co-organizer for the ResMed, Residential School on Medicinal Chemistry and Biology in Drug Discovery, a week-long graduate level course organized here at Drew University to provide an accelerated program for medicinal chemists, biologists and other industrial and academic scientists who wish to broaden their knowledge of drug discovery and development.

B. Positions and Honors

1971-1975 National Institute of Health Pre-Doctoral Assistantship, Columbia University 1975-1979 Senior Research Chemist, Department of Natural Product Chemistry, Merck Research Laboratories 1979-1983 Research Fellow, Department of Natural Product Chemistry, Merck Research Laboratories 1983-1985 Associate Director I, Department of Natural Products, Schering Plough Research Institute 1985-1989 Associate Director II, Department of Natural Products, Schering Plough Research Institute 1989-1997 Director, Department of High Throughput Screening and Natural Products, Schering Plough Research Institute 1997-2003 Senior Director, Department of New Lead Discovery, Schering Plough Research Institute 2004-2006 Vice President, Drug Discovery, Cetek Corporation 2007-2008 Chief Scientific Officer, Advanced Viral Research Corporation 2010-2011 Consultant, Chromocell Corporation 2007- Research Fellow, Research Institute for Scientists Emeriti, Drew University 2009- Consultant, Novobiotic Pharmaceuticals, LLC

Other Experience and Professional Memberships 1971- Member of the American Chemical Society (ACS) 1999- ACS Awards Review Committee for the Nakanishi Prize 1983- Member of the American Society for Microbiology (ASM) 1992-1993 Chair Fermentation and Biotechnology Division (ASM) 1996 Grant reviewer for the Natural Product Study Session, NIH 1989-1994 Council Member of the New York Academy of Sciences 1983- Member of the Society for Industrial Microbiology & Biotechnology (SIMB) 1992-1997 Special Conference Chair (SIMB) 1995-1998 Board of Directors (SIMB) 1999-2000 President (SIMB) 1999- Member of the awards committee (SIMB) 2009 Grant reviewer for International Cooperative Biodiversity Grants (ICBG) – NIH 2009- Consultant for Novobiotics Pharmaceutical, Cambridge MA 2010- 2011 Consultant for Chromocell Corporation, North Brunswick NJ 2008- Co-Chair, Residential School on Medicinal Chemistry & Biology in Drug Discovery, Drew University

Honors 1967-1971 Dean’s List 1970 National Science Foundation Undergraduate Research Participant 1971 Phi Beta Kappa, Magna cum Laude, Graduated with Honors, City College of NY 1971-1975 National Institute of Health Pre-Doctoral Assistantship 1986-1999 Founding Senior Editor for the Journal of Industrial Microbiology and Biotechnology 2011 Charles Porter Award (SIMB)

C. Contributions to Science

1. Deducing the structures of complex natural products that do not crystallize or when only small quantities are available is challenging. The use of NMR spectroscopic techniques has evolved over

many decades and currently addresses this problem. The initial steps involved the first application of 13C NMR as well as 1H studies for natural product structure elucidation. We applied 13C NMR for the structure elucidation of several complex natural products and were the first to utilize carbon relaxation times to deduce the types of carbons present in these molecules.

a. Structure of Prieurianin. NMR at Nonambient Temperature and X-Ray Structure Determination. V. Gullo, I. Miura, K. Nakanishi, A.F. Cameron, J.P. Connolly, F.D. Duncanson, A.E. Harding, R. McCrindle and D.A.H. Taylor. J.C.S., Chem Commun., 345 (1975). b. Structure of Two Triterpenes. Application of Partially Relaxed Fourier Transform CMR. K. Nakanishi, V.P. Gullo, I. Miura, T.R. Govindachari and N. Viswanathan. J. Amer. Chem. Soc., 95:6473 (1973). c. Modification of the Structure of Bussein. R. Hanni, C. Tamm, V. Gullo and K. Nakanishi. J.C.S., Chem. Commun., 563 (1975). d. Structures of Gonyautoxin II and III from the East Coast Toxic Dinoflagellate Gonyaulax tamarensis. Y. Shimizu, L. Buckley, M. Alma, Y. Oshima, W. Fallon, H. Kasai, I. Miura, V. Gullo and K. Nakanishi. J. Amer. Chem. Soc., 98:5414 (1976). e. Structural Studies of Triterpenoids. V.P. Gullo, Ph.D. Thesis, Columbia University, New York, New York, 1975.

2. Developing new purification methods to identify and purify therapeutic natural products. For thienamycin (primaxin), a novel, gentle ion-exchange separation was designed using aqueous carbon dioxide (cold, carbonic acid) to isolate this unstable natural product. To discover novel analogs of mevinolin (mevacor), derivatization with a UV absorbing chromophore was developed in order to detect these new compounds by HPLC. a. Procedure for the Isolation of Thienamycin from Fermentation Broths. L. Treiber, V. Gullo and I. Putter. Biotechnology and Bioengineering Vol. XXIII, 1255 (1981). b. U.S. Patent 4,198,338. Process for Purifying Thienamycin. L. Treiber and V. Gullo. c. High Performance Liquid Chromatographic Analysis of Derivatized Hypochoesteremic Agents from Fermentation Broths. V.P. Gullo, R. Goegelman, I. Putter and Y.K. Lam. J. Chromatography, 21:234 (1981). d. U.S. Patent 4,343,814. Hypocholesterolemic Fermentation Products. V. Gullo, T. Lam and R. Monaghan. e. U.S. Patent 4,432,996. Hypocholesterolemic Fermentation Products and Process of Preparation. V. Gullo, T. Lam and R. Monaghan.

3. Discovery of numerous natural products with diverse therapeutic potential. My role varied over my career. Initially, I worked in the laboratory developing methods and purifying biologically active natural products. This work contributed to the discovery and development of 3 marketed products, primaxin (antibacterial), mevacor (statin) and ivermectin (anthelmintic). Subsequently, I lead both a natural products discovery group and a high throughput screening group that discovered numerous lead compounds for many therapeutic targets. From the natural products program the most important compound discovered was Ziracin, a novel oligosaccharide antibacterial that progressed to Phase III clinical trials. From the high throughput screening group, the most important compound discovered was the anti-thrombotic medicine, vorapaxar.

a. EP 538011. Lipophilic Oligosaccharide Antibiotic Salt Compositions. V. Gullo, R. Hare, H. Kwon, D. Loebenberg, G. Miller, J. Morton and M. Patel b. Isolation and Characterization of Novel Oligosaccharides Related to Ziracin. M. Chu, R. Mierzwa, R. Jenkins, T.M. Chan, P. Das, B. Pramanik, M. Patel and V. Gullo. J. Nat. Prod. 65:1588-93 (2002). c. Exploiting New Approaches for Natural Product Drug Discovery in the Biotechnology Industry. V. Gullo and Dallas Hughes. Drug Discovery Today: Technologies, 2:281-286 (2005). d. Drug Discovery from Natural Products. Gullo VP, McAlpine J, Lam KS, Petersen F. J. Ind. Microbio. Biotechnol. 33: 523-531(2006).

Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/

D. Additional Information: Research Support and/or Scholastic Performance